Zotarolimus [CAS 221877-54-9]

Zotarolimus (ABT-578) is a derivative of Rapamycin , with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis[1][2].

[221877-54-9]

C52H79N5O12

966.21

CO[C@H]1[C@@H](N2C=NN=N2)CC[C@@H](C[C@H]([C@@](CC([C@@H](/C=C([C@H]([C@H](C([C@@H](C[C@@H]3C)C)=O)OC)O)\C)C)=O)([H])OC([C@@](CCCC4)([H])N4C(C([C@](O[C@]5([H])C[C@@H](/C(C)=C/C=C/C=C/3)OC)([C@@H](CC5)C)O)=O)=O)=O)C)C1

Drug Derivative

98.59

DMSO : 100 mg/mL (ultrasonic)

-20°C, 3 years (Powder)

Blue Ice